Neo Kuma Ventures

Neo Kuma Ventures, established in 2020 and based in London, United Kingdom, is a pioneering venture capital firm that exclusively invests in the psychedelic healthcare sector. Focused on European markets, the firm targets investments in psychedelic therapeutic compounds, clinics, care delivery systems, and digital therapeutics. With a commitment to advancing mental health treatment through innovative approaches, Neo Kuma Ventures has already made ten investments and continues to explore additional opportunities in this emerging field.

Fergus Argyle

Investor

Clara Burtenshaw

Co-Founder, Investor and Partner

Sean McLintock

Co-Founder, Investor and Partner

7 past transactions

Syndi

Pre Seed Round in 2023
Syndi is a digital health platform that focuses on enhancing health outcomes through technology and research, initially targeting mental health. The platform employs machine learning and digital phenotyping to provide personalized and immediate care by utilizing moment-by-moment passive smartphone data collection. This approach allows for effective and accessible support tailored to individual needs. Syndi's services aim to improve the treatment of invisible disabilities by facilitating connections between patients and healthcare providers, while also measuring the effectiveness of its applications and digital services. Through its innovative solutions, Syndi seeks to transform the way people access and engage with healthcare.

Kanna Health

Convertible Note in 2022
Kanna Health is a preclinical stage biotechnology company focused on developing innovative therapeutics derived from kanna, or Sceletium tortuosum, a medicinal succulent used for centuries by the San hunter-gatherers of South Africa. The company aims to address significant unmet needs in sexual and mental health through its lead candidate, KH-001, which is based on alkaloids found in kanna. This candidate is designed to enhance mood and performance in men, offering potential treatments that are both effective and affordable.

Fluence

Seed Round in 2021
Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge of the mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend.

Wavepaths

Seed Round in 2021
Wavepaths is a London-based company established in 2018 that focuses on creating innovative tools for psychedelic therapy aimed at facilitating inner exploration and personal transformation. The company develops a unique application that auto-generates individualized soundtracks for drug-free therapy sessions, integrating immersive media with advancements in intelligent technology and psychedelic science. By combining these elements, Wavepaths offers mobile tools and physical environments designed to help users reconnect with their inner resources, fostering meaningful introspection and emotional reconnection. The company's work lies at the intersection of information technology, healthcare, and personal health, emphasizing accessibility and personal growth through therapeutic experiences.

Journey Clinical

Seed Round in 2021
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.

Monument Therapeutics

Seed Round in 2021
Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to enhance patient identification by reducing heterogeneity and targeting those with similar underlying neurobiological conditions. This approach allows researchers to concentrate on advancing treatments in areas with significant unmet medical needs within the field of neuroscience.

Tripp

Series A in 2021
Tripp Inc. is a company focused on developing a digital psychedelic wellness platform that utilizes virtual and augmented reality to enhance emotional well-being. Founded in 2016 and headquartered in Los Angeles, California, with a satellite office in Chicago, the company creates immersive experiences that combine audio, visual elements, and gameplay mechanics to promote mindfulness and transformation. Tripp’s offerings are informed by scientific research indicating that interactive digital experiences can positively influence brain function. Through its platform, the company delivers wellness solutions designed to help users manage their emotions, reduce stress and anxiety, and achieve a state of calm and focus.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.